February 2020 updates to the website

The website has now been updated following February's LSCMMG

The following guidelines have been added/updated:

Lancashire and South Cumbria Self-Care and Access to OTC Medicines - Template Policy - New

Asthma Treatment Guideline for Children - New

Azathioprine and Mercaptopurine Shared Care Document - Update

Antipsychotic Shared Care Document - Update

Testosterone Shared care Document - Update

The following Items will be ratified and added to the website following March’s Joint Committee of CCGs (JCCCG) Meeting:

Octreotide - Secretory gastrointestinal disorders

Lanreotide - Secretory gastrointestinal disorders

Oscillating Positive Expiratory Pressure Devices - For Non – Cystic Fibrosis Bronchiectasis

Agomelatine - For the Treatment of Major Depressive Episodes in Adults

Nortriptyline - Chronic Neuropathic Pain

Lanreotide - Postural Tachycardia Syndrome (PoTS)

Octreotide - Postural Tachycardia Syndrome (PoTS)

Melatonin MR Tablets - Treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

Melatonin liquid 1mg/ml - All indications including insomnia and Jet Lag

Melatonin 3mg tablets - All indications including insomnia and Jet Lag

Lusutrombopag (TA617) - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure